Henry Kotula

JULY 1, 2019

The trend has implications for employers, payers, providers and even pharmaceutical and life science companies. For payers, it becomes important to benchmark the prices paid commercially against a common reference point such as Medicare. WHAT ELSE YOU SHOULD KNOW.

Life Science 32

Life Science Pharmaceuticals Mental health Telemedicine 32

Health Populi

OCTOBER 8, 2019

More savings would accrue through the quicker adoption of value-based payment models, the authors assert, where clinicians take on financial risk for managing population health. The Centers for Medicare and Medicaid Services (CMS) forecasts that prescription drug spending will be the fastest-growing cause of rising health spending by 2027.

Pharmaceuticals 271

Pharmaceuticals Medicare Life Science Health Policy 271

Health Populi

JANUARY 18, 2021

The public health crisis, combined with Medicare Advantage and other payors’ regimes, supported an economic model for the hospital-to-home movement. Even before the COVID-19 pandemic, more hospitals were piloting and planning to move inpatient acute care to certain patients’ home when that made clinical and economic sense.

Digital Health 194

Digital Health Public Health Life Science Patient Experience 194

Health Populi

JUNE 18, 2020

The authors, Dr. Naci and Dr. Kesselheim, are affiliated with the London School of Economics and Brigham and Women’s Hospital in Boston, note that 1% of medicines dispensed under Medicare Part D and Medicaid accounted for nearly $1 in $3 of drug spending in each program in 2015. bn to $32.8 bn to $9.9 bn for Medicaid.

BioTech 199

BioTech Medicare Life Science Telehealth 199

Health Populi

MARCH 6, 2019

is prescription drug prices — that they’re too high, that the Federal government should negotiate to lower costs for Medicare enrollees, and that out-of-pocket costs for drugs should be limited. One of the only issues bringing people together in the U.S.

Pharmaceuticals 149

Pharmaceuticals Life Science Medicare BioTech 149

Health Populi

JUNE 3, 2021

adults note that expanding Medicare to including hearing aids, dental and vision coverage would be their top or an important priority, shown in the second line in the bar chart on public priorities. States to negotiate with drug companies to get lower prices on Rx meds in their state, and. On the cost-front, 90% of U.S.

Medicare 177

Medicare Life Science BioTech Pharmaceuticals 177

Health Populi

FEBRUARY 4, 2020

voters in 2020 quite like supporting Medicare’s ability to negotiate drug prices with pharmaceutical companies, shown by the October 2019 Kaiser Family Foundation Health Tracking Poll. In this poll, the top strategy is via Medicare negotiation, above re-importation, reference pricing, and other tactics gauged in the survey.

Pharmaceuticals 207

Pharmaceuticals Medicare Leadership Life Science 207

Health Populi

MAY 19, 2019

They don’t tend to shop around for health care or be super-engaged in their care, probably because they tend to be older and more likely to be covered by Medicare. They may be threatened by a call for “Medicare for All” given their affection for the program.

Life Science 159

Life Science BioTech Medicare Medical Billing 159